- Clinical surveillance solution is designed to identify emergent patient deterioration and offer enhanced patient data visibility, flexible viewing options, and clinical decision support
- Facilitates remote patient oversightat mobile, eICU and virtual care clinical touchpoints
- New FDA clearance covers additional use cases and information access methods
Amsterdam, the Netherlands—Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced today at HIMSS22 that the latest Philips Capsule Surveillance solution has received 510(k) market clearance from the U.S. Food & Drug Administration (FDA), paving the way for widespread deployment across healthcare systems in the USA.